Latest action: Received in the Senate and Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Originating chamber has voted to pass. Sent to the other chamber.
The House voted to pass the bill. It now moves to the Senate, which repeats the committee referral and floor-vote process.
Next: Passed Both Chambers
Conference committee (if versions differ), then the President
Establishes safety standards for human cells and tissues used in medical products.
The problem
Human cell and tissue products used in medicine lack consistent federal safety oversight, creating risks for patients receiving these treatments.
The proposal
Creates federal safety requirements and regulations for human cell and tissue products to ensure they meet quality and safety standards before use.
The impact
Patients receive safer medical treatments. Medical companies must follow new rules. Healthcare providers must comply with regulations. Researchers may face new requirements.
Establishes clear safety standards for cell and tissue products used in medical treatment. Reduces risk of contaminated or unsafe products reaching patients. Provides federal oversight where gaps currently exist.
Creates uniform rules across states and companies for handling human cells and tissues. Prevents companies from using different safety standards in different locations. Gives manufacturers clear requirements to follow.
Federal safety standards may increase confidence in cell and tissue-based medical treatments. Clear regulations can reduce consumer uncertainty about product quality. Transparent oversight supports informed patient decisions.
Establishes predictable rules that companies know they must follow. Clear standards can actually support growth in the biotech and regenerative medicine industries. Provides safe framework for new treatments to develop.
New safety compliance requirements will increase expenses for medical companies and hospitals. Smaller companies may struggle with implementation costs. These costs could be passed to patients through higher treatment prices.
New approval and compliance processes could delay patient access to beneficial cell and tissue treatments. Lengthy regulations might slow the pace of medical innovation. Patients waiting for emerging therapies could experience longer delays.
Bill summary is not available, making it difficult to assess specific requirements and compliance expectations. Regulations may be interpreted differently by various agencies or states. Unclear rules create confusion for businesses trying to comply.
Stricter U.S. regulations could make American companies less competitive against international manufacturers. Companies may relocate operations to countries with fewer requirements. This could reduce domestic medical manufacturing jobs.
Generated by AI from the bill text. Not a prediction and not legal or policy advice. The percentage is the model's own rating of each item — self-reported, and not a measure of how accurate it is.
Loading map…
Loading...
0 citizens have already voted
Free · No spam · See how your representatives voted
Be the first to weigh in
Your vote starts the conversation
How citizen engagement works
Citizens vote & comment
Public opinion data is aggregated and updated in real time.
Patterns become visible
Representatives can see constituent sentiment broken down by district.
Your voice on the record
Contact your rep directly — one constituent call can shift a staffer's priority list.
Research shows that constituent contacts — especially calls — are among the most effective ways to influence a legislator's position on active bills.
Individual contributions, grouped by employer · FEC
Where their individual donors work · 2026 cycle
Money from people who work there, not from the company. Not tied to this bill.
Itemized individual contributions via FEC, grouped by the employer each contributor self-reported. Companies and unions cannot contribute to federal candidates from their treasuries, so these totals are money from people who work at an employer — never from the organization itself. They are campaign contributions covering a full election cycle and are not connected to this bill.
Senate LDA lobbying disclosures
Couldn't load lobbying disclosures right now.